Rhoneil Pena

508 total citations
9 papers, 30 citations indexed

About

Rhoneil Pena is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rhoneil Pena has authored 9 papers receiving a total of 30 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rhoneil Pena's work include Cancer Immunotherapy and Biomarkers (6 papers), Immune Cell Function and Interaction (4 papers) and Immunotherapy and Immune Responses (4 papers). Rhoneil Pena is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Immune Cell Function and Interaction (4 papers) and Immunotherapy and Immune Responses (4 papers). Rhoneil Pena collaborates with scholars based in United States. Rhoneil Pena's co-authors include Jonathan Zalevsky, Saul Kivimäe, Werner Rubas, Neel K. Anand, Grace Kim, Christie Fanton, Nancy Gordon, Eugenie S. Kleinerman, Loui Madakamutil and Haiying Cai and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Rhoneil Pena

8 papers receiving 30 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rhoneil Pena United States	3	19	18	7	5	4	9	30
Aliya Holland United States	4	14 0.7×	20 1.1×	5 0.7×		9 2.3×	5	38
Michelle Wantoch United Kingdom	2	12 0.6×	6 0.3×	7 1.0×		4 1.0×	2	23
Carl Watson Switzerland	3	25 1.3×	33 1.8×	6 0.9×		6 1.5×	3	49
Jan Eckmann Switzerland	3	15 0.8×	18 1.0×	2 0.3×		11 2.8×	5	34
Xiangji Wu China	3	23 1.2×	15 0.8×	6 0.9×		17 4.3×	4	47
Mignonette H. Macabali United States	3	30 1.6×	22 1.2×	7 1.0×		14 3.5×	5	39
Sarah Warren United States	3	32 1.7×	19 1.1×	10 1.4×		5 1.3×	6	43
Kristine Jähne Germany	3	10 0.5×	17 0.9×	3 0.4×		6 1.5×	7	25
Jennifer Ploski United Kingdom	2	9 0.5×	7 0.4×	2 0.3×	2 0.4×	5 1.3×	5	27

Countries citing papers authored by Rhoneil Pena

Since Specialization

Citations

This map shows the geographic impact of Rhoneil Pena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhoneil Pena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhoneil Pena more than expected).

Fields of papers citing papers by Rhoneil Pena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhoneil Pena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhoneil Pena. The network helps show where Rhoneil Pena may publish in the future.

Co-authorship network of co-authors of Rhoneil Pena

This figure shows the co-authorship network connecting the top 25 collaborators of Rhoneil Pena. A scholar is included among the top collaborators of Rhoneil Pena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhoneil Pena. Rhoneil Pena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Yuan, Robert, Andrew McGeehan, Sihong Zhou, et al.. (2025). The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death. Molecular Cancer Therapeutics. 24(9). 1428–1441. 1 indexed citations

Yuan, Robert, Andrew McGeehan, Sihong Zhou, et al.. (2025). Data from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death.

Kundra, Vikas, Murali K. Ravoori, John Stewart, et al.. (2020). Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma. International Journal of Cancer. 148(8). 1928–1937. 11 indexed citations

Miyazaki, Takahiro, Saul Kivimäe, Rhoneil Pena, et al.. (2019). NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model. Blood. 134(Supplement_1). 5302–5302. 4 indexed citations

Kivimäe, Saul, Rhoneil Pena, Yolanda Kirksey, et al.. (2018). Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214. Cancer Research. 78(13_Supplement). 3755–3755. 10 indexed citations

Charych, Deborah H., Werner Rubas, Vidula Dixit, et al.. (2016). Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor.. Journal of Clinical Oncology. 34(15_suppl). 11545–11545. 1 indexed citations

Langowski, John L., Murali K. Addepalli, Laurie A. VanderVeen, et al.. (2016). Abstract B057: The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity. Cancer Immunology Research. 4(11_Supplement). B057–B057. 1 indexed citations

Langowski, John L., Rhoneil Pena, Yolanda Kirksey, et al.. (2016). Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade. Cancer Research. 76(14_Supplement). 558–558. 1 indexed citations

Kantak, Seema, Steve Lee, Murali K. Addepalli, et al.. (2014). Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.. Journal of Clinical Oncology. 32(15_suppl). 3082–3082. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact